Zymeworks Inc. (ZYME) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to ZymeWorks first quarter 2026 results conference call. At this time, all participants are in the listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during your session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, Please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Chanel Inmadar, VP of Investor Relations. Your line is open. Thank you, Operator. Good afternoon, everyone, and thank you for joining our first quarter 2026 results conference call. As usual, I'd like to remind you that we'll be making a number of forward-looking statements during this call, including without limitation those forward-looking statements identified on our slides and the accompanying oral commentary. These forward-looking statements are based upon our current expectations and various assumptions and are subject to the risks and uncertainties including those associated with companies in our industry and at our stage of development. For a discussion of these risks and uncertainties, we'll refer you to our latest SUT filings as found on our website and as followed by the SUT. In a moment, I'll hand over the call to Ken Galbraith, our Chair and CEO, who will provide an overview of recent business updates. Ken will then hand the call over to Kristen Stafford, our Chief Financial Officer, to discuss our cash position and financial results for the first quarter of 2026. Dr. Paul Moore will then provide a brief summary of new preclinical data disclosed at AACR on our PAN RAS...